1) to evaluate the efficacy of a 3-month treatment with single-pill combination (SPC) perindopril arginine/amlodipine; 2) to correlate the predicted cardiovascular risk based on ASCORE, a hypertensive patient–specific risk score, with the vascular age based on SCORE, an indicator that is readily understandable by patients; 3) to assess the influence of blood pressure control with SPC on vascular age between baseline and month 3 after introduction of SPC perindopril arginine/amlodipine treatment; 4) to evaluate the adherence to treatment.Design and method:
The patients taking part in the program (n = 1340, 560 men [42%], 780 women [58%] were followed by physicians in the Russian Federation. The duration of treatment was 3 months. The parameters recorded were: systolic and diastolic arterial blood pressure, rate of achievement of BP < 140/90 mmHg, vascular age, cardiovascular risk assessed using the ASCORE scale, adherence to treatment assessed by the adherence scale, and biochemical parameters.Results:
After 3 months, BP was decreased by 34.9/16.7 mmHg on average (from 164.4 ± 13.1/96.0 ± 8.9 mmHg to 129.5 ± 9.2/79.3 ± 6.8 mmHg) (P < 0.00001). Target BP was achieved in 79.51% of patients. There was a significant decrease in vascular age from 66.6 ± 12.1 to 58.2 ± 10.0 years (P < 0.00001). Cardiovascular risk also decreased from 6.5 ± 4.3% to 4.0 ± 2.6% (P < 0.00001). This was due to improved patient adherence to treatment (the percentage of patients with high adherence increased from 23.8% to 62.1%). During the study, significant (P < 0.00001) reductions were recorded for total cholesterol, from 6.1 ± 1.1 mmol/l to 5.1 ± 0.8 mmol/l; glucose, from 5.55 ± 1.2 to 5.2 ± 0.8 mmol/l; creatinine, from 89.9 ± 18.2 mmol/l to 85.5 ± 15,4 mmol/l; and there was an increase in HDL-cholesterol from 1.5 ± 0.6 mmol/l to 1.6 ± 0.6 mmol/l.Conclusions:
This study demonstrated that treatment with SPC perindopril arginine/amlodipine effectively lowers BP at 3 months, with an associated decrease in vascular age and cardiovascular risk. Vascular age is an easy-to-use concept that improves patients’ understanding of cardiovascular risk, which, as a result, leads to improved patient adherence to treatment. A significant decrease in vascular age could be an important factor to improve doctor-patient communication.